Heartflow (HTFL) CEO Farquhar John C.M. Sells $1.9M of Stock

CEO John C.M. Farquhar sold 38,900 shares of Heartflow, Inc. (NasdaqGS: HTFL) on October 12, 2026, for about $1.93 million at a price of $49.57 per share. This sale fits into a pattern of insider trading as Farquhar had sold shares earlier in September.

Inside Farquhar's Trade

Farquhar's recent transaction involved selling 38,900 shares, valued at $1,921,195.2. This sale was made under a planned arrangement, which means it was likely pre-scheduled and not a reaction to market conditions.

Other Institutional Activity in Heartflow

Several institutional investors have adjusted their positions in Heartflow recently. Blackrock Inc. increased its holdings by 3,735,159 shares, bringing its total to 5,197,747 shares valued at about $251 million. Meanwhile, Vanguard Portfolio Management LLC added 1,538,522 shares, increasing its stake to 3,584,428 shares worth approximately $173 million. In contrast, Bain Capital Life Sciences Investors, LLC reduced its holdings by 1,999,725 shares, ending with 8,448,158 shares valued at about $408 million.

Heartflow, Inc. Stock Down 3.7%

As of October 16, 2026, Heartflow's stock was recently trading around $49, which is above its 50-day moving average by 5.5%. However, it remains about 9.8% below its 52-week high of $54.32. The stock has shown resilience, trading well above its 52-week low of $20.13.

Recent Earnings

Heartflow reported trailing twelve-month revenue of $212 million, showing a year-over-year revenue growth of 47.6%. However, the company has a negative net margin of -55.8%, and its return on equity stands at -154.2%. The next earnings report is set for November 11, 2026.

Insider Buying and Selling at Heartflow, Inc.

In addition to Farquhar's recent sale, other insiders have also sold shares. On September 11, 2026, Farquhar sold 38,900 shares before this transaction, while Chief Financial Officer Vikram Verghese sold 34,975 shares on September 15, 2026. Another officer, Campbell M.D. Rogers, sold 19,682 shares on September 18, 2026, at $50.15 each.

Analysts Set New Price Targets

Analysts have maintained their positive outlook on Heartflow. On September 22, 2026, Canaccord Genuity maintained a Buy rating with a new price target of $56, up from $45. Morgan Stanley also maintained an Equal-Weight rating with a target of $40. The consensus among analysts suggests a positive sentiment, with a mean price target of $47.22 based on nine opinions.

About Heartflow, Inc.

Heartflow, Inc. is a medical technology company based in San Francisco, CA. It specializes in non-invasive solutions for diagnosing and managing coronary artery diseases. The company uses artificial intelligence and computational fluid dynamics to create personalized 3D models of patients' hearts from specialized scans.

Bottom Line

Investors should keep an eye on Heartflow's upcoming earnings report on November 11, 2026, as well as any further insider trading activity. Farquhar's planned sale adds to the context of his earlier trades, indicating a strategic approach to stock management.